A computational study of non-coding RNAs on the regulation of activating transcription factor 3 in human breast cancer cells

被引:10
|
作者
Akshaya, R. L. [1 ]
Akshaya, N. [1 ]
Selvamurugan, N. [1 ]
机构
[1] SRM Inst Sci & Technol, Coll Engn & Technol, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India
关键词
Breast cancer; ATF3; miRNA; lncRNA; circRNA; EPITHELIAL-MESENCHYMAL TRANSITION; GENE-REGULATION; EXPRESSION; ATF3; PREDICTION; DATABASE; SPONGE; CERNA;
D O I
10.1016/j.compbiolchem.2020.107386
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We previously reported that activating transcription factor 3 (ATF3), an adaptive response gene, plays a dichotomous role in regulating several molecular processes during breast cancer progression. ATF3 promoted the expression of runt-related transcription factor 2 (Runx2, a metastatic gene) and activated matrix metalloproteinase 13 (MMP13, an invasive gene), thereby fostering proliferation and bone-metastasis of the breast cancer cells. Targeting ATF3 may mitigate the metastatic spread of breast cancer and improve the patient's lifespan. Non-coding RNAs (ncRNAs) such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) are the new-era regimens that are currently utilized for diagnosis and treatment of a variety of malignancies including cancer. mir-3674 putatively targets ATF3, but its expression was significantly increased in human breast cancer cells (MDA-MB231), compared to normal human mammary epithelial cells (MCF-10A). Our in silico analysis identified a few lncRNAs and circRNAs showing their putative binding sites for miR-3674. Thus, mir-3674, despite its abundance in the MDA-MB231 cells, could not effectively target ATF3, which could be due to the sponging mechanism of lncRNAs and circRNAs towards mir-3674. More extensive in vitro and in vivo studies are required to validate this and expand the diagnostic and therapeutic perspectives of breast cancer.
引用
收藏
页数:9
相关论文
共 50 条
  • [11] Angiogenesis regulation by microRNAs and long non-coding RNAs in human breast cancer
    Chong, Zhi Xiong
    Yeap, Swee Keong
    Ho, Wan Yong
    PATHOLOGY RESEARCH AND PRACTICE, 2021, 219
  • [12] Emerging role of non-coding RNAs in response of cancer cells to radiotherapy
    Ebahimzadeh, Kaveh
    Shoorei, Hamed
    Mousavinejad, Seyed Ali
    Anamag, Farhad Tondro
    Dinger, Marcel E.
    Taheri, Mohammad
    Ghafouri-Fard, Soudeh
    PATHOLOGY RESEARCH AND PRACTICE, 2021, 218
  • [13] The role of long non-coding RNAs in breast cancer microenvironment
    Yao, Wenwu
    Wang, Lin
    Liu, Fang
    Xia, Lin
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 248
  • [14] A systematic review of long non-coding RNAs with a potential role in breast cancer
    Heidari, Reza
    Akbariqomi, Mostafa
    Asgari, Yazdan
    Ebrahimi, Diako
    Alinejad-Rokny, Hamid
    MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2021, 787
  • [15] Vitamin D and Non-coding RNAs: New Insights into the Regulation of Breast Cancer
    Shahrzad, Mohammad Karim
    Gharehgozlou, Reyhaneh
    Fadaei, Sara
    Hajian, Parastoo
    Mirzaei, Hamid Reza
    CURRENT MOLECULAR MEDICINE, 2021, 21 (03) : 194 - 210
  • [16] Non-coding RNAs in cancer stem cells
    Yan, Huiwen
    Bu, Pengcheng
    CANCER LETTERS, 2018, 421 : 121 - 126
  • [17] Plant long non-coding RNAs in the regulation of transcription
    Chekanova, Julia A.
    NON-CODING GENOME, 2021, 65 (04): : 751 - 760
  • [18] Long non-coding RNAs in breast cancer stem cells
    Huang, Yuting
    Mo, Wenju
    Ding, Xiaowen
    Ding, Yuqin
    MEDICAL ONCOLOGY, 2023, 40 (06)
  • [19] Metformin and long non-coding RNAs in breast cancer
    Gholami, Morteza
    Klashami, Zeynab Nickhah
    Ebrahimi, Pirooz
    Mahboobipour, Amir Ali
    Farid, Amir Salehi
    Vahidi, Aida
    Zoughi, Marziyeh
    Asadi, Mojgan
    Amoli, Mahsa M.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [20] Potential therapies for non-coding RNAs in breast cancer
    Li, Ruonan
    Ji, Yuxin
    Ye, Ruyin
    Tang, Guohui
    Wang, Wenrui
    Chen, Changjie
    Yang, Qingling
    FRONTIERS IN ONCOLOGY, 2024, 14